Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters.

Franklin A ValderaAnne E O'SheaTodd R SmolinskyElizabeth L CarpenterAlexandra A AdamsPatrick M McCarthyAnkur TiwariRobert C ChickPhillip M Kemp BohanSpencer Van DecarKatryna K ThomasJulia O BaderGeorge E PeoplesGuy T CliftonAlex StojadinovicDaniel W NelsonTimothy J Vreeland

Published in: Journal of surgical oncology (2023)

Use and timing of MC contribute to OS in PDAC with an improved 5-year OS compared to SC. The greatest predictor of receiving MC was being given as NA therapy and the greatest survival benefit was the NA MC subgroup. Randomized studies evaluating the timing of effective MC in PDAC are needed.

Keyphrases

phase iii
open label
randomized controlled trial
squamous cell carcinoma
locally advanced
cell therapy
replacement therapy